Accepted for Publication: March 13, 2021.
Published Online: June 23, 2021. doi:10.1001/jamasurg.2021.2373
Correction: This article was corrected on August 3, 2022, to amend data in a figure.
Corresponding Author: Jianhua Fu, MD, PhD, Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Esophageal Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province 510060, China (firstname.lastname@example.org).
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Yang H et al. JAMA Surgery.
Author Contributions: Drs Fu and M. Liu (senior coauthors) had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Hong Yang, H. Liu, Y. Chen, Zhu, Fang, and Yu contributed equally and should be considered first coauthors.
Concept and design: Hong Yang, H. Liu, Zhu, Fang, Yu, Xiang, Han, Z. Chen, Zhang, Fu.
Acquisition, analysis, or interpretation of data: Hong Yang, H. Liu, Y. Chen, Fang, W. Mao, Xiang, Han, Z. Chen, Haihua Yang, J. Wang, Pang, Zheng, Huanjun Yang, T. Li, Q. Li, G. Wang, B. Chen, T. Mao, Kong, Guo, Lin, M. Liu, Fu.
Drafting of the manuscript: Hong Yang, H. Liu, Fang, Xiang, Han, Z. Chen, J. Wang, T. Mao, Lin, Fu.
Critical revision of the manuscript for important intellectual content: Hong Yang, H. Liu, Y. Chen, Zhu, Fang, Yu, W. Mao, Xiang, Han, Haihua Yang, Pang, Zheng, Huanjun Yang, T. Li, Zhang, Q. Li, G. Wang, B. Chen, Kong, Guo, M. Liu, Fu.
Statistical analysis: Hong Yang, Fang, Xiang, Han, Lin, M. Liu, Fu.
Obtained funding: Xiang, Fu.
Administrative, technical, or material support: Y. Chen, Zhu, Yu, W. Mao, Xiang, Han, Z. Chen, Haihua Yang, Huanjun Yang, T. Li, Q. Li, G. Wang, B. Chen, T. Mao, Kong, Guo, Lin, Fu.
Supervision: H. Liu, Y. Chen, Xiang, Han, Pang, Zhang, Lin, Fu.
Conflict of Interest Disclosures: None reported.
Funding/Support: This clinical trial was supported by grant 179 from the Health Ministry of China (Dr Fu), grant 2007048 from the Sun Yat-sen University Clinical Research 5010 Program (Dr Fu), grant 81272635 from the National Science Foundation of China (Dr Fu), grant 2012A030400007 from the Science and Technology Fund for Projects of Guangdong Province (Dr Fu), and grant 2011C13039-2 from the Major Science and Technology Special Fund for Projects of Zhejiang Province (Dr Zhu).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: Nonauthor investigators in the Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010 (NEOCRTEC5010) Randomized Clinical Trial Group: Yonghong Hu, MD, Qiaoqiao Li, MD, Mian Xi, MD, Liru He, MD, Bo Qiu, MD, and Shiliang Liu, MD, Department of Radiation Oncology, Sun Yat-sen University Cancer Center; Xiaodong Li, MD, Kongjia Luo, MD, Junying Chen, MD, Yihuai Hu, MD, Jiyang Chen, BS, and Caiyan Fang, MD, Department of Thoracic Surgery, Sun Yat-sen University Cancer Center; Wenfeng Ye, MD, Department of Clinical Nutrition, Sun Yat-sen University Cancer Center; Jing Wen, PhD, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Ruiqi Wang, MD, Department of Pancreatic and Biliary Surgery, Sun Yat-sen University Cancer Center; Xuan Xie, MD, Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Fu Yang, MD, Department of Thoracic Surgery, Shanghai General Hospital; Feixiang Wang, MD, Department of Thoracic Surgery, Cancer Center of Guangzhou Medical University; Shihua Yao, MD, Department of Thoracic Surgery, Changhai Hospital; Peng Tang, MD, Zhao Ma, MD, Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital; Longlong Shao, MD, Department of Thoracic Surgery, Fudan University Shanghai Cancer Center; and Lin Peng, Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute.
Meeting Presentations: The results of this study were presented in part at the annual meeting of the European Society for Medical Oncology; October 8, 2016; Copenhagen, Denmark and the 25th annual meeting of the European Society of Thoracic Surgeons; May 30, 2017; Innsbruck, Austria.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank the members of the independent data monitoring committee, Tiehua Rong, MD, Qing Liu, PhD, and Yuhong Li, MD, of the Sun Yat-sen University Cancer Center. We also thank Jibin Li, PhD, of the Sun Yat-sen University Cancer Center, for his assistance with the statistical analysis. None of the contributors received compensation.
F , Ferlay
J , Soerjomataram
I , Siegel
RL , Torre
LA , Jemal
A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
. 2018;68(6):394-424. doi:10.3322/caac.21492
J , van Lanschot
JJB , Hulshof
et al; CROSS Study Group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol
. 2015;16(9):1090-1098. doi:10.1016/S1470-2045(15)00040-6
KM , Burmeister
BH , Smithers
et al; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol
. 2011;12(7):681-692. doi:10.1016/S1470-2045(11)70142-5
C , Puttisak
P , Preecha
N . A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology
. 1994;41(4):391-393.PubMedGoogle Scholar
SG , Orringer
MB , Turrisi
A , Iannettoni
M , Forastiere
A , Strawderman
M . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol
. 2001;19(2):305-313. doi:10.1200/JCO.2001.19.2.305
JL , Park
SI , Kim
et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol
. 2004;15(6):947-954. doi:10.1093/annonc/mdh219
BH , Smithers
BM , Gebski
et al; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol
. 2005;6(9):659-668. doi:10.1016/S1470-2045(05)70288-6
J , Krasna
MJ , Niedzwiecki
et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol
. 2008;26(7):1086-1092. doi:10.1200/JCO.2007.12.9593
C , Dahan
L , Mornex
et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol
. 2014;32(23):2416-2422. doi:10.1200/JCO.2013.53.6532
H , Liu
H , Chen
et al; AME Thoracic Surgery Collaborative Group. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol
. 2018;36(27):2796-2803. doi:10.1200/JCO.2018.79.1483
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. American Joint Committee on Cancer; 2002.
Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3. Division of Cancer Treatment and Diagnosis, National Cancer Institute; 2006.
H , Fu
JH , Hu
et al. [Neo-adjuvant chemoradiotherapy followed by surgery in treatment of advanced esophageal carcinoma]. Zhonghua Yi Xue Za Zhi
. 2008;88(45):3182-3185.PubMedGoogle Scholar
N , Iizuka
T , Ide
et al; Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol
. 2003;21(24):4592-4596. doi:10.1200/JCO.2003.12.095
B , Hu
H , Zhang
et al. Extended right thoracic approach compared with limited left thoracic approach for patients with middle and lower esophageal squamous cell carcinoma: three-year survival of a prospective, randomized, open-label trial. Ann Surg
. 2018;267(5):826-832. doi:10.1097/SLA.0000000000002280
ED , Dunne
B , Griffin
M , Keeling
N , Reynolds
JV . Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. Eur J Surg Oncol
. 2004;30(3):313-317. doi:10.1016/j.ejso.2003.11.009Crossref
X , He
W , Yang
et al. Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus: from the results of NEOCRTEC5010, a randomized multicenter study. Ann Surg
. Published online December 17, 2019. doi:10.1097/SLA.0000000000003727
P , Clark PJ. Neo-adjuvant treatment for oesophageal cancer. 1999;3(4):231-238.
Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet
. 2002;359(9319):1727-1733. doi:10.1016/S0140-6736(02)08651-8Crossref
WH , Stenning
SP , Bancewicz
J , Clark
PI , Langley
RE . Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol
. 2009;27(30):5062-5067. doi:10.1200/JCO.2009.22.2083
DP , Winter
KA , Gunderson
et al; Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol
. 2007;25(24):3719-3725. doi:10.1200/JCO.2006.10.4760
K , Kato
K , Igaki
et al; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol
. 2013;43(7):752-755. doi:10.1093/jjco/hyt061